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Abstract
Background: Bacterial meningitis (BM) is a serious, life-threatening infectious disease of the central nervous system
that often occurs in young children. The most common severe to moderate sequelae following BM are sensorineural
hearing loss, neuromotor disabilities and mental retardation, while subtle sequelae include academic and behavioral
disabilities. It is largely unknown whether these more subtle sequelae persist into adolescence and adulthood.
Therefore, this study will investigate the very long-term effects of childhood BM in later life. Better understanding of
long-term effects and early identification of adverse outcomes after BM are essential for more timely interventions.
Additionally, certain single nucleotide polymorphisms (SNPs) are associated with disease severity and might predict
adverse sequelae. These include SNPs in genes encoding for pathogen recognition and immune response upon
infection. Accordingly, a secondary objective of this study is to investigate the role of genetic variation in BM and use
any insights to predict short- and long-term outcomes.
Methods: In the Dutch 20|30 Postmeningitis study, adolescents and young adults (n = 947) from two historical cohorts
with a prior episode of BM during childhood will be enrolled into a cross-sectional follow-up investigation using mainly
questionnaires that examine executive and behavioral functioning, health-related quality of life, subjective hearing,
mood and sleeping disorders, academic performance, and economic self-sufficiency. The results will be compared to
normative data by one-sample t-tests. Multivariable regression analysis will be used to assess for any associations with
causative pathogens and severity of BM. Participants that complete the questionnaires will be approached to provide a
swab for buccal DNA and subsequent sequencing analyses. Logistic regression models will be used to predict sequelae.
Discussion: The unique follow-up duration of this cohort will enable us to gain insights into the possible very long-term
adverse effects of childhood BM and how these might impact on quality of life. The investigation of host genetic factors
will contribute to the development of prediction models which will serve as prognostic tools to identify children who are
at high risk of adverse outcome after BM.
Trial Registration: Dutch Trial Register NTR-6891. Retrospectively registered 28 December 2017.
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Background
Bacterial meningitis (BM) is a severe infection of the central
nervous system that mainly affects infants and young
children. Specifically in the Netherlands, where this study is
based, estimates indicate there are ~ 205 new cases of BM
in children annually [1]. The incidence of acute
community-acquired BM is 0.9–2.6 per 100,000 per year in
high-income countries [2, 3]. Incidence rates have dropped
dramatically in the Netherlands [4] over the years, espe-
cially following the introduction of a vaccination campaign
that started in 1993 that targeted Haemophilus influenzae
type b, a major causative agent of BM in young children.
Other common pathogens involved in BM are Neisseria
meningitidis and Streptococcus pneumoniae. Meanwhile,
Streptococcus agalactiae is the predominant pathogen in
neonates younger than 1 month of age [3].
Children who survive BM often have severe to moderate
or mild sequelae, with reported rates varying from 10 to
20% [5–8]. The most common severe sequelae are profound
hearing impairment, neuromotor disabilities (e.g. spasticity),
blindness, and mental retardation [5–11]. More subtle
sequelae are reported in 20–30% of children who have had
BM [8, 10, 12–14]. These include cognitive impairment,
academic or behavioural disabilities and fine motor issues.
Previous research shows that the sequelae of BM contrib-
ute to a lower score in health-related quality of life in Dutch
children [12]. Moreover, it is likely that mild disabilities due
to BM in childhood have serious effects on social participa-
tion and quality of life during adulthood [12, 14–16]. Like-
wise, academic and behavioural limitations might result in
a less rewarding career and greater prospects later in life.
For example, mild disabilities may result in loss of product-
ivity, a lower perceived health-related quality of life and
might ultimately lead to an increased burden on society
and the social health care system.
In general terms, investigations into the very long-
term effects of BM from childhood into adulthood are
limited [17]. This means general practitioners and adult
survivors of childhood BM have little empirical evidence
to use when considering the very long-term conse-
quences of BM. Additionally, parents often feel that a
comprehensive explanation of the possible after-effects
is needed on discharge from hospital and also find
uncertain prognoses difficult to handle [18]. Some of the
existing studies on the long-term outcomes after BM
show that deficits in verbal IQ, full-scale IQ, numeracy
and functional ability are all possible outcomes [19–21]..
The current study will investigate the long-term health
and quality of life outcomes following childhood BM.
Specifically, the study will focus on outcomes during
adolescence and young adulthood in two historical co-
horts that survived childhood BM.
In addition, the study will also explore genetic varia-
tions relating to innate immunity that might influence
longer-term outcomes following BM. Our research
group previously found that single nucleotide polymor-
phisms (SNPs) in the Toll-like receptor 4 and 2 genes
(TLR4 and TLR2) are highly associated with susceptibil-
ity to meningococcal meningitis in children [22]. More-
over, SNPs in the genes for TLRs 2, 4, and 9 are highly
associated with sensorineural hearing loss in survivors of
childhood BM [23]. Activation and stimulation of TLRs
at the site of infection results in the production of cyto-
kines and chemokines. TLR2 binds to protein porin B
which is present on the outer membrane of N. meningi-
tidis and also binds lipoteichoic acid that is localized in
the cell wall of S. pneumoniae [24]. TLR4 is activated by
lipopolysaccharide in the outer membrane of N. menin-
gitidis and pneumococcal lysin [25]. TLR9 is an intracel-
lular pathogen recognition receptor which recognizes
CpG (non-methylated cytosine-phosphate-guanine)
motifs in bacterial DNA [26]. Mutated variants may
enhance susceptibility caused by hypo-responsiveness to
pathogens but on the contrary, may also lead to protec-
tion if variants enhance the crucial initiation of the
inflammatory response against pathogens. In order to
use host genetic factors in prediction models for out-
comes after BM, more genetic variants should be studied
to create the best subset of variants with the strongest
predictive potential. Therefore, the secondary objective
of this study is to investigate genetic variants and their
role in susceptibility to BM and whether they can be
used to predict outcomes after BM.
Methods/Design
Objective
The main objective of this study is to determine whether
BM in childhood is associated with impaired functioning
in adolescence and young adulthood and to identify chil-
dren most at risk of developing adverse outcomes. It will
particularly focus on subtle sequelae and also examine
host genetic factors and clinical variables.
Key questions
During a period of 2 years the following study questions
will be addressed:
1. What is the health-related quality of life and partici-
pation in society of BM survivors approximately 25
years after infection?
2. To what degree is BM in childhood associated with
adverse health-related quality of life in young adult-
hood, when quality of life is compared to that of a
general adult population?
3. To what degree is adverse quality of life (compared
to a general adult population) related to the age of
onset and the pathogen causing BM?
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4. What is the degree of economic burden in young
adulthood after childhood BM, in terms of income,
health-care utilization, and absenteeism from study
or work?
5. Which SNPs (alone or in a genetic trait) in immune
response genes are associated with susceptibility to
and severity of BM, and other related long-term
outcomes?
Setting
In 1999, a study was initiated in The Netherlands to deter-
mine the incidence of adverse consequences after child-
hood BM. This had a focus on the prediction of changes in
hearing loss, academic achievement and behavioral limita-
tions at school-age (see timeline displayed in Fig. 1). In
1999 and 2005, two cohorts of childhood BM survivors of
school age were constructed as part of this study. Both co-
horts are used in the present study and were retrospectively
selected based on data from analyses of bacterial cerebro-
spinal fluid (CSF) isolates from the Netherlands Reference
Laboratory for Bacterial Meningitis (NRLBM). These iso-
lates were obtained from patients treated for BM in 110
Dutch hospitals. For the first cohort, files of the NRLBM
were searched for children born between January 1986 and
December 1994 who survived BM between January 1990
and December 1995 (see Fig. 2). 1605 children were eligible
for inclusion and pediatricians were approached to send
their parents a letter requesting participation. 628 children
were included and their medical records were investigated
for risk factors and for perceptive hearing loss of > 25 dB
[12]. The second cohort consisted of 361 children born be-
tween January 1993 and December 1999 who suffered from
non-haemophilus type b BM between January 1997 and
December 2001 (see Fig. 3 and Table 1) [27]. This second
cohort was mainly constructed for the external validation
of earlier constructed prediction models for outcomes after
childhood BM.
In 2006, both cohorts were approached to participate
in a follow-up study to collect genetic data by analyzing
buccal DNA. A total of 471 patients (70%) returned a
buccal swab. The methodology used to construct these
cohorts is extensively described in earlier published
studies [12, 27, 28]. All patients from the original co-
horts who consented to future follow-up studies will be
invited for the present study.
Study population
The parents of 624 patients of the first cohort agreed to
participate in further studies. During the last follow-up
round 38 parents could not be reached. The remaining
586 young adults will be invited to participate in the
present study (see Table 1). Median age of all patients at
infection was 2.1 (IQR] 0.8–3.8) years. At the time of the
present study, all patients will have a median age of
years 26 (IQR 22.0–28.0) (see Table 1). Participants will
be censored when contact details cannot be retrieved
from the municipal registers.
Collection of information
The original study was initiated in 1999, indicating that
the addresses of the patients might need to be updated
in order to perform the current study. Local municipal
registers will be used for this update. The patients will
receive a letter in which information is stated about the
relevance, procedure of the study and a link to complete
the online internet-based questionnaires. The patients
will be asked to sign an online informed consent form.
Study subjects can revoke their informed consent to par-
ticipate at any time without explanation.
At baseline, information was obtained from medical
records, and in 2006, parents of children from the
Fig. 1 Timeline Blue circle: previous studies. Yellow circle: current study.
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second cohort completed the Child Behaviour Checklist
(CBCL) and the Strengths and Difficulties Question-
naires (SDQ) [12, 29]. The questionnaires in the present
study will focus on the following six domains: health-
related quality of life including participation in society,
hearing, cognitive function, academic achievement,
behavioral functioning and economic burden.
Health-related quality of life
To determine health-related quality of life and participation
in society the following questionnaires will be used: the
Global Health 10 PROMIS (Patient Reported Outcomes
Measurement Information System)-29 Profile question-
naire, PROMIS Satisfaction 2.0 questionnaire and the
Weiss functional Impairment Rating Scale Self-Report
(WFIRS-S) [30, 31].
Hearing
A slightly modified used to examine subjective hearing.
The adjustments included changes to questions to focus on
adolescents and young adults that did not solely focus on
hearing aid adjustments. Originally developed for adults
[32–34], the AIADH is a self-assessment questionnaire that
consists of 28 items covering all the relevant factors of
disability in individual hearing functioning in daily life.
AIADH has high validity and reliability, according to previ-
ous research [33].
Fig. 2 Flowchart Cohort 1
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Academic achievement and cognitive functioning
Academic achievement will be examined with questions
related to type of school, history of school career (e.g.
what kind of primary and secondary school did they at-
tend, and did they participate in subsequent education).
Executive functions will be measured by Behaviour Rat-
ing Inventory of Executive Function-Adult Version
(BRIEF-A). This consists of a self-assessment and an
informant list of questions which both consist of 75
items. The items cover behavioural regulation (inhib-
ition, flexibility, regulation of emotion, self-evaluation)
and metacognition (taking initiative, working memory,
planning and organizing, job evaluation, orderliness) [35,
36].
Behavioural functioning
The Adult Self Report (ASR) is a 126-item self-report
questionnaire for adults (ages 18–59) that assesses aspects
of adaptive functioning and problems. The questionnaire
provides scores for the following syndrome scales: anx-
ious/depressed, withdrawn, somatic complaints, thought
problems, attention problems, aggressive behavior, rule-
breaking behavior, and intrusive behavior. The question-
naire provides scores for the following DSM- oriented
scales: depressive problems, anxiety problems, somatic
problems, avoidant personality problems, attention deficit/
hyperactivity problems (inattention and hyperactivity/im-
pulsivity subscales), and antisocial personality problems.
Additionally, the questionnaire asks about the use of the
following substances: tobacco, alcohol, and drugs. The
CBCL and the ASR are part of a system of comparable in-
struments in terms of content, administration and scoring.
Fig. 3 Flowchart Cohort 2
Table 1 Overview of meningitis cohort
Cohort 1 N = 586
Median age 28.0 (IQR 27.0–30.0)
Male* 335 (57)
Female* 251 (43)
Cohort 2 N = 361
Median age 22.0 (IQR 21.0–24.0)
Male* 200 (55)
Female* 161 (45)
Total cohort present study N = 947
Median age 26.0 (IQR 22.0–28.0)
Male* 535 (56)
Female* 412 (44)
*Values represent numbers (percentages)
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Health-care utilization and absenteeism from study-work
The Institute for Medical Technology Assessment (iMTA)
Productivity Cost Questionnaire (iPCQ) and iMTAMedical
Consumption Questionnaire (iMCQ) will be used to meas-
ure the impact of BM on the ability of a person to perform
work. The iMCQ is a generic instrument for measuring
medical costs and includes questions relating to frequently
occurring contacts with health care providers. The iPCQ
measures and values productivity losses [37, 38].
Collection of samples
Participants that complete the questionnaires will be
approached to provide a swab for buccal DNA. DNA
will be isolated from the buccal swabs and analysed
using Kompetitive Allele specific polymerase chain reac-
tion technology (KASP). A selection of 20–40 SNPs will
be typed within and downstream the TLR signalling
pathway but also within genes involved in the produc-
tion of inflammation cytokines (e.g. IL-1).
Statistical analysis
Data processing
Data will be assessed for the potential for bias due to non-
response and the extent of missing data. Univariable com-
parisons of the distribution of patient characteristics and
clinical data will be performed with independent one
sample-t-tests for continuous data and χ2-test for nominal
data. Fisher’s exact test will be used if the data does not
meet the criteria for a χ2-test. In general, data will be pre-
sented as mean (standard deviation) for normally distrib-
uted variables, and as median (IQR) for continuous
variables that are not normally distributed. Normality of
the distribution of the data will be assessed by evaluating
distribution plots and the Shapiro–Wilk test.
Prediction of quality of life
The results of all individual questionnaires (except
iMCQ and iPCQ since these questionnaires are not vali-
dated yet) will be compared to the general population
using one-sample t-tests or the one-sample Wilcoxon
signed rank test, depending on normality of distribution
of the data [30, 34, 36, 39]. Comparisons of quality of life
health-care utilization, absenteeism, executive function-
ing, academic achievement and behavioural functioning
will be made between cases (patients with and without
hearing loss at baseline). Multiple regression analysis will
be used to examine associations of functioning in daily
life (WFIRS-S) with quality of life (PROMIS Global
health) adjusting for the following potential confounders:
birth weight, administration of dexamethasone during
infection, gestational age, type of antibiotics, education
level of parents, socio-economic status, current age, age
of onset and severity of sequelae. All associations will be
explored for differences in effect between male and
female, but also for differences in effect between causal
pathogens with stratified analysis and interaction tests.
Prediction of the course of behavioral (dis-)functioning
To determine the course of behavioral, dis-functioning,
a one sample paired t-test will be performed on the sec-
ond cohort as we will have data from both the ASR and
the CBCL. Multiple regression analysis will be used to
examine associations between behavioral functioning
(ASR) and quality of life (PROMIS Global Health ques-
tionnaire) adjusting for the following potential con-
founders: education level of parents, school results and
executive functioning. All associations will be explored
for differences in effect between male and female, but
also for differences in effect between causal pathogens
with stratified analysis and interaction tests.
Analysis of genetic data
Combined carriage of two or more SNPs will also be in-
vestigated to determine whether certain traits are associ-
ated with outcomes after BM. The lasso method will be
used to determine the potential predictive value of SNPs
and to assess the association with susceptibility. This is a
statistical method to reliably select variables when there
are more variables than outcome categories (also called
the events per variable problem) [40]. Regression ana-
lysis will be used to assess significant differences, while
hearing will be used as an outcome variable. All results
will be considered statistically significant if a two-sided
p-value of < 0.05 is reached. The Hardy-Weinberg equi-
librium will be applied to assess Mendelian inheritance.
Discussion
During the Dutch 20|30 Postmeningitis study, the very
long-term effects after childhood BM will be investigated
in two historical cohorts with an individual follow-up
time of up to ~ 25 years. The questionnaires will provide
data on health-related quality of life including participa-
tion in society, hearing, cognitive functioning, academic
achievement, behavioural functioning, economic self-
sufficiency, and utilization of medical care. More insight
into long-term outcomes after childhood BM is needed
to better align the follow-up of these children and will
also enable clinicians to inform parents and address im-
portant long-term consequences of childhood BM. Chil-
dren at high risk of developing sequelae should be
identified at an early stage after experiencing BM in
order to provide timely interventions or prevent compli-
cations. Single nucleotide polymorphisms seem a valu-
able addition to clinical prediction models [41, 42]. By
further exploring genetic variation in patients with BM
the best set of variants with the strongest predictive po-
tential can be assembled.
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Strengths
The 20|30 Dutch Postmeningitis study will be the first to
investigate quality of life after childhood BM in historical
cohorts with a follow-up of approximately 25 years. The
follow-up duration in combination with the several do-
mains assessed with questionnaires should make this study
valuable from multiple perspectives. In particular, economic
self-sufficiency and medical treatment use at such a long
outlook have not been investigated. As such, this study will
provide new information on very long-term outcomes after
BM and potentially guide the clinical follow-up of children
who experience BM. There is no consensus currently on
which children should be followed over time and for how
long. Clearly, clinicians will keep observing and treating
children with severe sequelae. However, in the case of chil-
dren with more subtle sequelae the picture is less clear
when considering longer term outcomes. Extended infor-
mation on the course of mild sequelae after BM would be
beneficial from a clinical perspective. Specifically, know-
ledge of risk factors that contribute to long-term care after
BM would also be valuable.
Limitations
First of all, the genetic domains that we will investigate
should be carefully considered as associations with child-
hood BM because of the cross-sectional study design
and the fact that this study lacks a control group. To de-
termine possible long-term adverse effects of childhood
BM in young adulthood it would be better to study all
domains at several moments in time. Furthermore, there
is a risk of selection bias as patients with less or more
sequelae might be more motivated to participate in this
study. There is also a risk that participation with the on-
line questionnaires might limit the participation of pa-
tients with more profound sequelae. In addition, both
historical cohorts used in this study had an overall dif-
ference in age and were not treated at the same time.
In summary
BM is still a life-threatening infectious disease and this
study will provide more insight into the very long-term
outcomes which could have a significant impact on sub-
sequent health state of childhood BM survivors during
young adult life. Prediction of the outcomes using host
genetic risk factors and clinical variables may contribute
to better understanding, timely intervention and thereby
appropriate follow-up of children after BM.
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